Literature DB >> 29500705

Primary management of atypical meningioma: treatment patterns and survival outcomes by patient age.

Ernest Barthélemy1, Joshua Loewenstern1, Neeraja Konuthula2, Margaret Pain1, Jordan Hall1, Satish Govindaraj2, Joshua Bederson1, Raj K Shrivastava3,4,5.   

Abstract

PURPOSE: The initial management of atypical meningiomas poses a distinct clinical challenge in that treatment protocols have not been fully established, and outcomes, especially differences by patient age, have not been broadly measured. The National Cancer Database (NCDB) allows for analysis of a large, diverse patient population to determine clinical parameters and survival outcomes based on the initial treatment of patients with atypical meningiomas.
METHODS: Analysis of the NCDB yielded 3611 atypical meningioma patients treated between 2008 and 2012. Principal treatment paradigms included surgery with or without radiation. Survival estimates were calculated using Kaplan-Meier curves stratified by age at diagnosis for each treatment paradigm. Subset analysis was performed for socio-economic factors.
RESULTS: Overall 5-year survival rate was 77.6% and declined with increasing patient age (p < 0.0001). Five-year survival for patients ≤ 45 years undergoing surgery alone was 89.3 vs. 44.4% for those > 75 years (p < 0.0001). For patients undergoing surgery with adjuvant radiation, 5-year survival was 93.7% in those ≤ 45 years and 54.1% in those > 75 years (p < 0.0001). Use of adjuvant radiation was stable over time. Private-insured patients were more likely to receive adjuvant radiation (p = 0.0001).
CONCLUSIONS: Patients treated for atypical meningioma have high rates of 5-year survival. A marginal survival benefit of adjuvant radiation was observed for patients < 55 and > 75 years, while patients between 55 and 75 years tended to have slightly improved survival with surgery alone. Though surgery remains the standard of care in the primary treatment of atypical meningioma, the decision to administer radiation post-operatively has remained controversial.

Entities:  

Keywords:  Age; Atypical meningioma; National Cancer Database; Survival; Treatment

Mesh:

Year:  2018        PMID: 29500705     DOI: 10.1007/s00432-018-2618-4

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  33 in total

1.  Atypical and anaplastic meningioma: outcomes in a population based study.

Authors:  T Garzon-Muvdi; W Yang; M Lim; H Brem; J Huang
Journal:  J Neurooncol       Date:  2017-04-20       Impact factor: 4.130

Review 2.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

Review 3.  The role of adjuvant radiotherapy after gross total resection of atypical meningiomas.

Authors:  Shaakir Hasan; Michael Young; Trevine Albert; Ashish H Shah; Christian Okoye; Amade Bregy; Simon S Lo; Fazilat Ishkanian; Ricardo J Komotar
Journal:  World Neurosurg       Date:  2014-12-19       Impact factor: 2.104

4.  Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases.

Authors:  L Palma; P Celli; C Franco; L Cervoni; G Cantore
Journal:  J Neurosurg       Date:  1997-05       Impact factor: 5.115

5.  Atypical and malignant meningioma: outcome and prognostic factors in 68 irradiated patients.

Authors:  Beatrice Detti; Silvia Scoccianti; Vanessa Di Cataldo; Eleonora Monteleone; Samantha Cipressi; Lorenzo Bordi; Gianni Pellicanò; Davide Gadda; Calogero Saieva; Daniela Greto; Guido Pecchioli; Annamaria Buccoliero; Marco Ceroti; Franco Ammannati; Giampaolo Biti
Journal:  J Neurooncol       Date:  2013-09-18       Impact factor: 4.130

6.  Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation.

Authors:  Manish K Aghi; Bob S Carter; Garth R Cosgrove; Robert G Ojemann; Sepideh Amin-Hanjani; Robert L Martuza; William T Curry; Fred G Barker
Journal:  Neurosurgery       Date:  2009-01       Impact factor: 4.654

Review 7.  Intracranial meningiomas of atypical (WHO grade II) histology.

Authors:  Leland Rogers; Mark Gilbert; Michael A Vogelbaum
Journal:  J Neurooncol       Date:  2010-08-26       Impact factor: 4.130

Review 8.  Treatment of malignant gliomas in elderly patients: a concise overview of the literature.

Authors:  Patrizia Farina; Giuseppe Lombardi; Eleonora Bergo; Anna Roma; Vittorina Zagonel
Journal:  Biomed Res Int       Date:  2014-04-22       Impact factor: 3.411

9.  Overall survival benefit associated with adjuvant radiotherapy in WHO grade II meningioma.

Authors:  Chenyang Wang; Tania B Kaprealian; John H Suh; Charlotte D Kubicky; Jeremy N Ciporen; Yiyi Chen; Jerry J Jaboin
Journal:  Neuro Oncol       Date:  2017-09-01       Impact factor: 12.300

10.  The pervasive crisis of diminishing radiation therapy access for vulnerable populations in the United States, part 1: African-American patients.

Authors:  Shearwood McClelland; Brandi R Page; Jerry J Jaboin; Christina H Chapman; Curtiland Deville; Charles R Thomas
Journal:  Adv Radiat Oncol       Date:  2017-08-03
View more
  8 in total

1.  Initial management of meningiomas: Analysis of the National Cancer Database.

Authors:  Catherine R Garcia; Stacey A Slone; Monica Chau; Janna H Neltner; Thomas Pittman; John L Villano
Journal:  Cancer Epidemiol       Date:  2019-03-14       Impact factor: 2.984

2.  Clinicopathologic Characteristics of Grade 2/3 Meningiomas: A Perspective on the Role of Next-Generation Sequencing.

Authors:  Junhyung Kim; Kihwan Hwang; Hyun Jung Kwon; Ji Eun Lee; Kyu Sang Lee; Gheeyoung Choe; Jung Ho Han; Chae-Yong Kim
Journal:  Front Oncol       Date:  2022-06-13       Impact factor: 5.738

3.  Prognostic Factors and Treatment Strategies for Elderly Patients with Malignant Meningioma: A SEER Population-Based Study.

Authors:  Songshan Feng; Jing Li; Fan Fan; Zeyu Wang; Qian Zhang; Hao Zhang; Ziyu Dai; Xun Zhang; Peng Luo; Zaoqu Liu; Jian Zhang; Zhuoyi Liu; Quan Cheng
Journal:  Front Oncol       Date:  2022-05-13       Impact factor: 5.738

4.  Nonmalignant and malignant meningioma incidence and survival in the elderly, 2005-2015, using the Central Brain Tumor Registry of the United States.

Authors:  Rebecca L Achey; Haley Gittleman; Julia Schroer; Vishesh Khanna; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2019-02-19       Impact factor: 12.300

Review 5.  Role of adjuvant radiotherapy in atypical (WHO grade II) and anaplastic (WHO grade III) meningiomas: a systematic review.

Authors:  P D Delgado-López; E M Corrales-García
Journal:  Clin Transl Oncol       Date:  2020-07-10       Impact factor: 3.405

6.  A Clinical Prognostic Model Based on Preoperative Hematological and Clinical Parameters Predicts the Progression of Primary WHO Grade II Meningioma.

Authors:  Peng Gao; Tengxiao Kong; Xuqiang Zhu; Yingwei Zhen; Hongjiang Li; Di Chen; Shanpeng Yuan; Dongtao Zhang; Henan Jiao; Xueyuan Li; Dongming Yan
Journal:  Front Oncol       Date:  2021-10-11       Impact factor: 6.244

7.  A Magnetic Resonance Imaging-Based Radiomic Model for the Noninvasive Preoperative Differentiation Between Transitional and Atypical Meningiomas.

Authors:  Jing Zhang; Guojin Zhang; Yuntai Cao; Jialiang Ren; Zhiyong Zhao; Tao Han; Kuntao Chen; Junlin Zhou
Journal:  Front Oncol       Date:  2022-01-21       Impact factor: 6.244

8.  Clinical Factors and Outcomes of Atypical Meningioma: A Population-Based Study.

Authors:  Gui-Jun Zhang; Xiao-Yin Liu; Chao You
Journal:  Front Oncol       Date:  2021-05-26       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.